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Previewsnetworks, such as that of MYC, remains
to be determined. While Rui et al. (2010)
showed that JAK2 inhibitors affect chro-
matin in PMBL and abrogate an onco-
genic program, whether these agents
affect MPN in the same manner remains
to be determined. On the horizon
are histone demethylase inhibitors. A
JMJDC2 inhibitor was recently identified
(Hamada et al., 2010), and it will be critical
to test the activity of such agents in
PMBL, HL, MPN, and other tumors that
harbor the 9p23-24 amplicon.
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Tvorogov et al. (2010) describe in this issue of Cancer Cell an antibody that inhibits homodimerization of
vascular endothelial growth factor receptor-3 (VEGFR-3) and its heterodimerization with VEGFR-2, but not
ligand binding. The work provides mechanistic insights into receptor dimerization and an approach to
suppress both angiogenesis and lymphangiogenesis.More than 800,000 cancer patients world-
wide are currently being treated with
angiogenesis inhibitors. Treatment with
the monoclonal antibody bevacizumab to
block vascular endothelial growth factor
(VEGF), a cytokine that promotes blood
vessel growth, delays progression, and
prolongs survival in some cancers (Bagri
et al., 2010). Other macromolecular thera-
peutics that block VEGF signaling, in-
cluding ramucirumab, an antibody that
targets VEGF receptor-2 (VEGFR-2), and
aflibercept, a chimeric decoy receptor
that binds VEGF, are in advanced clinical
trials (http://www.clinicaltrials.gov). These
agents are selective, are well tolerated,and generally have only modest side
effects restricted to consequences of
inhibiting VEGF in normal organs.
However, selective VEGF blockers are
efficacious in many cancers only when
administered in combination with chemo-
therapy, and tumors can progress while on
therapy. The slowing of tumor growth after
inhibition of VEGF signaling can be accom-
panied by increased invasiveness and
metastasis in some preclinical models
(Paez-Ribes et al., 2009). The mechanisms
of dependence on chemotherapy, progres-
sion during treatment, and exaggerated
aggressivenessareunclear,butmoreeffica-
ciousapproachesare actively being sought.Receptor-blocking antibodies that tar-
get the ligand-binding site of receptors
compete with the ligand. This type of
inhibitor has the potential limitation of
being less efficient at high ligand concen-
trations, when the ligand out-competes
the inhibitor. Because delivery of anti-
bodies to tumors is hampered by ineffi-
cient blood vessels, erratic blood flow,
and high intratumoral pressure, inhibitors
may not reach their molecular targets in
sufficient amount and uniformity to be fully
efficacious. In addition, other mecha-
nisms contribute to the limitations of
efficacy of angiogenesis inhibitors.
Factors other than VEGF can promoteecember 14, 2010 ª2010 Elsevier Inc. 541
Figure 1. Novel Strategy to Stop Angiogenesis and Lymphatic
Growth by Blocking Receptor Dimerization
VEGF binds to and activates VEGFR-2 on the cell surface, which promotes
angiogenesis. The antiligand antibody bevacizumab blocks VEGF. VEGF-C,
the VEGFR-3 ligand, can also bind to VEGFR-2, and promote receptor heter-
odimerization, downstream signaling, and endothelial cell sprouting. Conven-
tional inhibitory antibodies (Ab) to VEGFR-2 or VEGFR-3 block ligand binding
to extracellular domains 2 and 3. The report by Tvorogov and colleagues
describes a novel antibody 2E11 that is directed against the VEGFR-3 extra-
cellular domain 5 that inhibits VEGFR-3 homodimerization and VEGFR-2/
VEGFR-3 heterodimerization without blocking ligand binding. This inhibition
impairs both angiogenesis and lymphangiogenesis.
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invading tumors can co-opt
normal blood vessels. Even
when VEGF blockade slows
tumor angiogenesis, it does
not slow the growth of lym-
phatic vessels (lymphangio-
genesis) that serve as routes
for cancer cells to spread to
lymph nodes and distant
sites. Because lymphatic
metastases have detrimental
consequences, selective
inhibitors of lymphangiogene-
sis would complement angio-
genesis inhibitors, but none is
yet available for clinical use.
One strategy for increasing
efficacy is to block the spread
of tumor cells to local lymph
nodes. Lymphangiogenesis
is driven by VEGF-C and
VEGF-D, which signal
through VEGFR-3. VEGF-C
also promotes the formation
of VEGFR-2/VEGFR-3 heter-
odimers. Like VEGFR-2,
VEGFR-3 signaling can con-
tribute to angiogenesis in
tumors, in which the receptoris expressed on tumor blood vessels as
well as on lymphatics. Involvement of
VEGFR-3 in the growth of blood vessels
and lymphatics makes it a promising
candidate for cancer therapy. Inhibition
of lymphangiogenesis with a soluble
form of VEGFR-3 or monoclonal anti-
bodies that block receptor activation can
reduce lymphatic metastases by 50%–
70% in preclinical models (Tammela and
Alitalo, 2010). Monoclonal antibodies that
block binding of VEGF-C and VEGF-D to
VEGFR-3 can also suppress angiogen-
esis, and this action is strengthened
when used in combination with
a VEGFR-2-blocking antibody (Tammela
et al., 2008).
Findings in a report in this issue of
CancerCell (Tvorogovet al., 2010) indicate
that efficacy of angiogenesis inhibitors
may be increased through use of a combi-
nation of twodistinct classes of antibodies
directed toward functionally different
regionsof VEGF receptors (Figure 1). Tvor-
ogov and colleagues describe a novel
type of VEGFR-3-blocking antibody that
inhibits the dimerization of VEGFR-3,
which is an essential step in receptor
activation. Ligand binding causes VEGF542 Cancer Cell 18, December 14, 2010 ª20tyrosine kinase receptors to dimerize and
become activated through transphos-
phorylation (Lemmon and Schlessinger,
2010). Because VEGF ligands are dimers,
they can trigger monomers of VEGFR-2
and VEGFR-3 to bind one another to
form homodimers or heterodimers.
Findings by Tvorogov et al. show that
the novel antibody 2E11 inhibits the
formation of VEGFR-3 homodimers and
VEGFR-3/VEGFR-2 heterodimers but
does not inhibit binding of VEGF-C ligand
to VEGFR-3, unlike conventional re-
ceptor-blocking antibodies (Figure 1).
The activity of 2E11 was thus relatively
independent of ligand concentration. In-
deed, the antibody was able to suppress
VEGFR-3 activation at even higher con-
centrations of VEGF-C than those that
occur in tissues. Further experiments re-
vealed that the antibody binds to the
immunoglobulin-like domain 5 in the
extracellular part of VEGFR-3, which is
not involved in ligand binding. In VEGF
receptors, domains 2 and 3 contribute
solely to ligand-binding, but dimerization
involves the membrane proximal domain
7 (Lemmon and Schlessinger, 2010; Lep-
panen et al., 2010). Additional homotypic10 Elsevier Inc.interactions occur around
domain 4 in this class of
receptor, suggesting that
2E11 targeting of domain 5
disrupts these interactions
(Ruch et al., 2007).
Functional studies showed
that thedimerization-blocking
action of antibody 2E11 was
accompanied by inhibition
of VEGF-C-induced phos-
phorylation of VEGFR-3 and
suppression of signal trans-
duction and endothelial cell
migration and sprouting. The
antibody also suppressed
vascular network formation
from human endothelial cells
implanted in mice. Impor-
tantly, the receptor dimeriza-
tion-blocking antibody used
in combination with a ligand-
binding antibody produced
greater inhibition of VEGFR-3,
had synergistic inhibitory ef-
fects in some models, and in-
hibited endothelial sprouting
and angiogenic vascular net-
work formation more than
either antibody used alone.Therapeuticantibodies that target recep-
tors can act throughmultiple mechanisms.
Both clinically approved antibodies (cetux-
imab and panitumumab) that target EGFR
(ErbB1, HER1) compete with EGF ligand
by binding to domain 3 of the extracellular
part of EGFR. Successful interaction
blocks ligand binding and receptor activa-
tion. The antibody trastuzumab acts on
HER2 (ErbB2) through a mechanism not
involving inhibition of ligand binding, given
that no ligand for HER2 has been identified
and homodimerization does not occur.
Although the mechanism is not completely
understood, trastuzumabhas little effecton
heterodimerization. By contrast, another
HER2 blocking antibody, pertuzumab,
acts by blocking heterodimerization of
HER2 with HER3 (ErbB3) or another EGFR
family member (Hughes et al., 2009). This
difference in mechanism of action explains
why pertuzumab is effective in carcinomas
that express low levels of HER2, where
trastuzumab is not. Combinations of the
twoantibodiesproducemorepotent inhibi-
tion of proliferation and migration of tumor
cells and induce clustering of crosslinked
receptors without receptor activation, fol-
lowed by inhibition of receptor recycling
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et al., 2010). Antibody combinations are
now being tested in HER2-positive breast
cancer (http://www.clinicaltrials.gov).
Overall, the findings reported by Tvoro-
gov and colleagues define a novel class of
anti-VEGFR-3 antibody that blocks ho-
modimerization and heterodimerization
of receptors and complements the ac-
tivity of antibodies that block ligand-
binding. This work provides mechanistic
insights into receptor dimerization and
the promise of using inhibitors of dimer-
ization as a biologically meaningful ap-
proach for suppressing angiogenesis
and lymphangiogenesis and potentially
tumor growth and dissemination. Be-
cause VEGFR-3 is one of the most highly
upregulated therapeutic targets in endo-
thelial cells of tumor vessels, the receptor
could also serve as a target for antibodies
coupled to therapeutic cargo such as
radioisotopes, liposomes, or nanopar-
ticles loaded with cytotoxic therapeutics,
or even T cells.This novel class of inhibitors has the
potential of outperforming conventional
competitive inhibitors of angiogenesis
because of the insensitivity to ligand
concentration and the ability to inhibit
heterodimerization and influence multiple
downstream signaling pathways. The use
of an antidimerization antibody in combi-
nation with an antiligand binding antibody
could translate into clinical benefit from
more potent antiangiogenic and antilym-
phangiogenic activities. Further validation
of the efficacy of antibody combinations
in preclinical models could pave the way
for inhibitors that block tumor angiogen-
esis and lymph node metastasis in cancer
patients.
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In this issue of Cancer Cell, Anido et al. demonstrate that Id1 is the likely arbiter of divergent transforming
growth factor-b (TGF-b) signaling in glioma-initiating cells (GICs) from different tumors. These findings
hold both the promise and potential peril of therapeutic targeting of the TGF-b pathway.Human glioblastoma derived GICs have
stem cell properties of self-renewal and
differentiation with genotypes and pheno-
types similar to their parental tumors and
substantially different from conventional
glioma cell lines (Lee et al., 2006). In addi-
tion, there is evidence suggesting that
GICs can promote tumor angiogenesis
and mediate radiotherapy resistance
(Bao et al., 2006). With the increasing evi-
dence that GICs are the stem cell sub-
component of malignant gliomas, there
are reasons to believe that targeting
GICs hold great therapeutic potential.Terminal differentiation is a powerful
tumor suppressor mechanism, and thus
there is keen interest in finding ways to
activate cancer stem cell differentiation
programs for therapeutic purposes.
As the founding member of a group of
more than 40 secreted factor family
members, TGF-b plays an intricate role
in the regulation of almost all cell types
in the body, with an emphasis on control-
ling homeostasis and developmental
processes including stem cell differentia-
tion. The effects of TGF-b signaling
are mediated through transmembraneserine-threonine type I (TbRI) and type II
(TbRII) receptors that phosphorylate
Smad proteins, which then forward
signals from the TGF-b receptors to the
nucleus where they regulate transcription.
The role of TGFb in cancer stem cell differ-
entiation is of significant interest given its
overexpression in a number of tumors
including lung, colon, and gastric carci-
noma as well as in high-grade gliomas.
TGF-b had been previously shown to
increase the self-renewal and oncogenic
potential of GICs, although the mecha-
nism was not known (Penuelas et al.,ecember 14, 2010 ª2010 Elsevier Inc. 543
